LEXXW - Lexaria Strengthens its International Patent Portfolio to 19 Patents Granted
(TheNewswire)
New patent granted in Indiabolsters worldwide patent coverage, adding to existing patents in theEU, the U.S., and Australia
Kelowna, British Columbia – TheNewswire - May 12, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the“Company” or “Lexaria”), a global innovator in drug deliveryplatforms, announces further expansion of its intellectual propertyportfolio with its first-ever patent granted in India.
The patent is titled “ Stableready-to-drink beverage compositions comprising lipophilic activeagents” and is of particular importance giventhe size of the Indian population, which is nearly four times as largeas the U.S. population . The patent is valid for 20 years from the patentapplication date of Dec. 1, 2016.
“This is our 19 th patent grantedworldwide, allowing us to innovate in the ready-to-drink beveragecomposition category around the world,” saidChris Bunka, CEO of Lexaria. “This new patent complements ourexisting suite of granted patents spanning theEU, the U.S., and Australia, and provides intellectual propertyprotection to both consumer-packaged goods as well as registered drugapplications. We believe these are robust growth categories that addto Lexaria’s strategic value.”
This is the second patent granted from Lexaria’sthird patent family. Lexaria’s patent application suite has grown toa total of 13 patent families. Active ingredients that may be used under this newpatent include NSAIDS (e.g., acetylsalicylicacid, ibuprofen, diclofenac, indomethacin, piroxicam), fat-solublevitamins, and acetaminophen. Active ingredients under the new patentalso include nicotine and cannabinoids.
Claims granted cover a wide range of product formats,including non-carbonated beverages, carbonatedbeverages, colas, root beers, fruit-flavoured beverages,citrus-flavored beverages, fruit juices, fruit-containing beverages,vegetable juices, vegetable-containing beverages, teas, coffees, dairybeverages, protein-containing beverages, shakes, sports drinks, energydrinks, and flavored waters.
Lexaria has patent applications progressing incountries around the world with aggregate populations of approximately3.7 billion people and will report on further progress as informationbecomes available.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1–2 hours to minutes, and maskunwanted tastes. DehydraTECH is planned to be further evaluated fororally administered bioactive molecules, including anti-virals,cannabinoids, vitamins, non-steroidal anti-inflammatory drugs(NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiplecompanies, including a world-leading tobacco producer for thedevelopment of smokeless, oral-based nicotine products, and for use inindustries that produce cannabinoid beverages, edibles, and oralproducts. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfoliowith 19 patents granted and approximately 60 patents pendingworldwide. For more information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the Companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants, or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the U.S. Securities and Exchange Commission on EDGAR.There is no assurance that any of Lexaria’s postulated uses,benefits, or advantages for the patented and patent-pending technologywill in fact be realized in any manner or in any part. No statementherein has been evaluated by the Food and Drug Administration (FDA).Lexaria-associated products are not intended to diagnose, treat, cure,or prevent any disease. Any forward-looking statements contained inthis release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances, or otherwise,except as otherwise required by law.
TheCSE has not reviewed and does not accept responsibility for theadequacy or accuracy of this release.
INVESTOR CONTACT:
Copyright (c) 2021 TheNewswire - All rights reserved.